Cadrenal Therapeutics Files 8-K

Ticker: CVKD · Form: 8-K · Filed: Sep 25, 2024 · CIK: 1937993

Sentiment: neutral

Topics: 8-K, disclosure, corporate-events

Related Tickers: CADR

TL;DR

CADR filed an 8-K on 9/25 - check for updates.

AI Summary

Cadrenal Therapeutics, Inc. filed an 8-K on September 25, 2024, to report on several events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. Specific details regarding the nature of these events or any associated financial figures were not immediately available in the provided text.

Why It Matters

This 8-K filing indicates significant corporate activity or disclosures by Cadrenal Therapeutics, Inc. that could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: medium — 8-K filings can signal important, sometimes material, events that may affect a company's stock price.

Key Players & Entities

FAQ

What specific events are being disclosed under Regulation FD?

The provided text does not specify the exact nature of the Regulation FD disclosures made by Cadrenal Therapeutics, Inc. in this 8-K filing.

What are the 'Other Events' reported in this 8-K?

The filing indicates 'Other Events' are being reported, but the specific details of these events are not detailed in the provided excerpt.

What is the purpose of including 'Financial Statements and Exhibits' in this filing?

This item suggests that financial statements or exhibits relevant to the reported events are being provided as part of the 8-K filing.

When was the earliest event reported in this 8-K?

The earliest event reported in this 8-K filing occurred on September 25, 2024.

What is Cadrenal Therapeutics, Inc.'s principal executive office address?

Cadrenal Therapeutics, Inc.'s principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.

Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2024-09-25 16:05:31

Key Financial Figures

Filing Documents

01 Regulation

Item 7.01 Regulation FD Disclosure On September 25, 2024, Cadrenal Therapeutics, Inc. (the "Company") posted an updated corporate presentation within the Investor Relations section of the Company's website, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The updated corporate presentation includes information regarding the Company's plans for its Phase 3 trial in its lead targeted indication, patients with an approved left-ventricular assist device (LVAD), as well as two other targeted indications: patients with end stage kidney disease with atrial fibrillation, and mechanical heart valve patients with difficult-to-control time in therapeutic range or genetic resistance to warfarin. Representatives of the Company may use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01. Other Events

Item 8.01. Other Events. The updated corporate presentation includes information regarding the Company's plans for its Phase 3 trial in its lead targeted indication, patients with an approved left-ventricular assist device (LVAD), as well as two other targeted indications: patients with end stage kidney disease with atrial fibrillation and mechanical heart valve patients with difficult-to-control time in therapeutic range or genetic resistance to warfarin.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Investor Presentation of Cadrenal Therapeutics, Inc. dated September 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 25, 2024 CADRENAL THERAPEUTICS, INC. By: /s/ Quang Pham Name: Quang Pham Title: Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing